Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase Inhibitor

BACKGROUND: The non-receptor tyrosine kinase JAK2 is implicated in a group of myeloproliferative neoplasms including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. JAK2-selective inhibitors are currently being evaluated in clinical trials. Data from drug-resistant chronic m...

Descripción completa

Detalles Bibliográficos
Autores principales: Marit, Michael R., Chohan, Manprit, Matthew, Natasha, Huang, Kai, Kuntz, Douglas A., Rose, David R., Barber, Dwayne L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420867/
https://www.ncbi.nlm.nih.gov/pubmed/22916261
http://dx.doi.org/10.1371/journal.pone.0043437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420867/
https://www.ncbi.nlm.nih.gov/pubmed/22916261
http://dx.doi.org/10.1371/journal.pone.0043437

Ejemplares similares